←
Boltz190 posts
Boltz avatar

Boltz

@boltz_bio

With AI, we help every scientist reshape biology.

◷ Joined November 2024▧ 12 Photos and videos
Boltz avatar
Boltz@boltz_bio·Jan 8

Hello World 👋 Today we are unveiling Boltz PBC, a Public Benefit Corporation to advance AI for biology through open science, and make it accessible to every scientist building a healthier future. Follow to stay up to date, and read more on our manifesto: boltz.bio/manifesto

Big news from Boltz today: we’re launching Boltz Lab, a new platform with new small-molecule + protein design agents, announcing Boltz PBC and a $28M seed round, and sharing a multi-year partnership with Pfizer. More below! 🚀

Gabriele Corso avatar
⟳ Boltz retweeted
Gabriele Corso@GabriCorso·6h

With our Series A, we’re sharing Boltz Lab usage figures publicly for the first time. Thousands of scientists requested access within weeks of our January launch. Our June release of the BoltzMol-1 and BoltzProt-1 models accelerated adoption: Boltz molecular token usage is up 50-fold in less than five months as scientists replace a growing share of physical experiments with these models! 🧪

Post attachment
Jay Rughani avatar
⟳ Boltz retweeted
Jay Rughani@JayRughani·8h

Boltz raised $110M to help scientists design new medicines. - 100K+ scientists use Boltz models - Paying customers collectively use their models 50x more than in June - 6 of the world's top 20 pharmas have partnered with them Congrats @GabriCorso, @jeremyWohlwend and team!

We’ve raised $110M to bring AI-powered biomolecular design to every scientist! Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.

0:16
Elliot Hershberg avatar
⟳ Boltz retweeted
Elliot Hershberg@ElliotHershberg·8h

We are big believers in the @boltz_bio team and in their vision. After co-leading their Seed, we doubled down in their new $110M round. Onward!

Post attachmentPost attachment
Andrew Dunn avatar
⟳ Boltz retweeted
Andrew Dunn@AndrewE_Dunn·15h

EXCLUSIVE: Boltz says pharma usage of its AI drug design software is up 50x, raising a $110M Series A to double down and expand, @GabriCorso tells me My latest for @endpts on another major AI bio raise in London: endpoints.news/ai-bio-startu…

Andrew Dunn avatar
⟳ Boltz retweeted
Andrew Dunn@AndrewE_Dunn·15h

Boltz shared this data on usage, measured by molecular tokens processed. Fast growth over the past 2 months, and Boltz's leaders don't expect that to change anytime soon

Post attachment
Dylan Reid avatar
⟳ Boltz retweeted
Dylan Reid@dreidco·11h

@Boltz_Bio is building the token factory for molecules and medicine just raised $110M Series A from @BessemerVP, @a16z, @AmplifyPartners, @ObviousVC, @FPrimeCapital, @GreycroftVC and others to put the most powerful AI models in the hands of as many scientists as possible. Thrilled to double down on this incredible team and critically important mission at @ZettaVentures Congrats to @GabriCorso, @JeremyWohlwend, @Pas_Saro and the rest of the team!

We’ve raised $110M to bring AI-powered biomolecular design to every scientist! Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.

0:16
Jeremy Wohlwend avatar
⟳ Boltz retweeted
Jeremy Wohlwend@jeremyWohlwend·11h

We built Boltz to put our models in the hands of every scientist. This latest funding round is a major step toward that goal, giving us the resources to push our research further, build more powerful tools, and continue to grow our fantastic team.

We’ve raised $110M to bring AI-powered biomolecular design to every scientist! Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.

0:16
Byron Deeter avatar
⟳ Boltz retweeted
Byron Deeter@bdeeter·10h

Over 100K scientists trust @boltz_bio’s foundation models as part of their default toolkit for early-stage drug discovery. Every partnership Boltz has built so far started as inbound interest from computational chemists and biologists. Scientists put their faith in the models and @gabricorso, @jeremyWohlwend, @pas_saro long before the company existed. Bessemer is excited to partner with the team pioneering this field and lead Boltz’s $110M Series A to build toward programmable molecular design. Learn more: bessemervp.team/4zOozof

andrew hedin avatar
⟳ Boltz retweeted
andrew hedin@andrewhedin·10h

Code now gets written in AI-native tools. We think preclinical R&D follows. 6 of the top 20 pharma companies already use Boltz, and usage is up 50x since June. Proud to lead @boltz_bio's $110M Series A with @GabriCorso and team. Our thesis:

Bessemer @BessemerVP 11h Article Boltz: building towards programmable molecular design Bessemer Venture Partners leads @Boltz_bio's $110M Series A to back the team behind the state-of-the-art protein and small molecule foundation models for AI drug discovery. Two years ago, a small team

Liam Maniscalco avatar
⟳ Boltz retweeted
Liam Maniscalco@liammaniscalco·9h

So excited to be partnering with the amazing @boltz_bio team! Their models are playing a key part in how scientists drive towards early-stage drug discovery, and the adoption + growth has been incredible to see.📈

We’ve raised $110M to bring AI-powered biomolecular design to every scientist! Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.

0:16
Jorge Conde avatar
⟳ Boltz retweeted
Jorge Conde@JorgeCondeBio·12h

AI is now a consumable reagent for drug discovery: scientists can buy + use intelligence on demand via @boltz_bio molecular tokens. Molecular token usage up ~50x; deployed at 6 of top 20 pharma. $110M Series A led by @BessemerVP @a16z excited to double down! cc: @zakdoric

We’ve raised $110M to bring AI-powered biomolecular design to every scientist! Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.

0:16
Zak Doric avatar
⟳ Boltz retweeted
Zak Doric@zakdoric·12h

Congratulations to @boltz_bio on their $110M Series A, led by @BessemerVP Boltz makes frontier molecular intelligence available on demand, with molecular token usage up ~50x since June and deployments at 6 of the top 20 pharma. We @a16z are proud to double down! cc @JorgeCondeBio

We’ve raised $110M to bring AI-powered biomolecular design to every scientist! Boltz’s Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the world’s 20 largest pharma companies.

0:16